For the Inventor, By the Inventor

Enter assignee name

L'Aquila, Italy

Dompe Pha.r.ma S.p.a.

Calculating rank

USPTO Granted Patents = 14

% Expired Patents = 64.3

CIPO Patents = 5

Forward Citations = 49

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Marcello Allegretti (10 out of 42 patents)

Riccardo Bertini (10 out of 22 patents)

Maria Candida Cesta (10 out of 25 patents)

4. Cinzia Bizzarri (8 out of 18 patents)

5. Andrea Aramini (6 out of 27 patents)

6. Alessio Moriconi (6 out of 11 patents)

7. Francesco Colotta (6 out of 23 patents)

8. Cesare Di Palma (3 out of 3 patents)

9. Andrea Beccari (2 out of 9 patents)

10. Giovanni Del Re (2 out of 2 patents)

11. Matteo Putrignano (2 out of 2 patents)

12. Gabriele Di Giacomo (2 out of 2 patents)

13. Marco Maria Gentile (1 out of 6 patents)

14. Gianfranco Caselli (1 out of 28 patents)

15. Valerio Berdini (1 out of 2 patents)

14 patents: Sort by Forward Citations

1. 8648110 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them (2014-02-11),

2. 8440711 - 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them (2013-05-14),

3. 8288368 - Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells (2012-10-16),

4. 8063242 - 2-aryl-propionic acids and pharmaceutical compositions containing them (2011-11-22),

5. 8026367 - (R)-arylalkylamino derivatives and pharmaceutical compositions containing them (2011-09-27),

6. 7939521 - 2-arylpropionic acid derivatives and pharmaceutical compositions containing them (2011-05-10),

7. 7868046 - (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them (2011-01-11),

8. 7776909 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them (2010-08-17),

9. 7737139 - Sulfonic acids, their derivatives and pharmaceutical compositions containing them (2010-06-15),

10. 7652169 - (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them (2010-01-26),

11. 7635442 - Apparatus and method for micron and submicron particle formation (2009-12-22),

12. 7560487 - Use of (R)—ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs (2009-07-14),

13. 7250152 - Supercritical fluids processing: preparation of protein microparticles and their stablilisation (2007-07-31),

14. 7175886 - Apparatus and method for micron and submicron particle formation (2007-02-13),

Company Overview

Dompe Pha.r.ma S.p.a. is a biopharmaceutical company based in L'Aquila, Italy, specializing in the development and manufacturing of innovative therapies for rare diseases and serious medical conditions. The company focuses on areas such as pain management, ophthalmology, and regenerative medicine, leveraging advanced research and technology to create effective treatments. Dompe is committed to improving patient outcomes through its dedication to scientific excellence and collaboration within the global healthcare community.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

14 Patents

#2 in L'Aquila

#664 in Italy

#42,312 in the World

L'Aquila, Italy

Dompe Pha.r.ma S.p.a.

Forward Citations = 49

23 inventors:

Marcello Allegretti (10 out of 42 patents)

Riccardo Bertini (10 out of 22 patents)

Maria Candida Cesta (10 out of 25 patents)

4. Cinzia Bizzarri (8 out of 18 patents)

5. Andrea Aramini (6 out of 27 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dompe Pha.r.ma S.p.a.. Retrieved from https://idiyas.com/company/dompe-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…